Journal Club: Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus.

Afroditi BoulougouraHannah GendelmanNatalya SurmachevskaVasileios C Kyttaris

Published in: ACR open rheumatology (2023)

These data suggest that CD19 CAR-T cell therapy was feasible, tolerable, and effective in this small case series of refractory SLE. Nevertheless, larger placebo-controlled trials are warranted.

Keyphrases

systemic lupus erythematosus
cell therapy
disease activity
placebo controlled
mesenchymal stem cells
nk cells
double blind
electronic health record
big data
study protocol
squamous cell carcinoma
randomized controlled trial
radiation therapy
machine learning
data analysis
open label
locally advanced